CASI Pharmaceuticals (CASIF) Retained Earnings (2021 - 2025)

CASI Pharmaceuticals has reported Retained Earnings for 5 years, with the latest figure at -$748.1 million in Q4 2025.

• For the quarter ending Q4 2025, Retained Earnings fell 42072.1% year-over-year to -$748.1 million; the trailing twelve-month figure through Dec 2025 stood at -$748.1 million (down 42072.1% YoY), and the FY2025 full-year result was -$748.1 million, down 42072.1% from the prior year.
• Retained Earnings for Q4 2025 stood at -$748.1 million, down from -$735.1 million in the prior quarter.
• The five-year high for Retained Earnings was -$1.8 million in Q4 2024, with the low at -$710.8 billion in Q1 2025.
• Historically, Retained Earnings has averaged -$245.9 billion across 5 years, with a median of -$735.1 million in 2025.
• Annual changes were most pronounced in 2024 — Retained Earnings surged 100.0% — and 2025, when it slumped 105938.68%.
• CASI Pharmaceuticals' Retained Earnings stood at -$605.6 million in 2021, then retreated by 5.2% to -$637.2 million in 2022, then plunged by 103612.88% to -$660.8 billion in 2023, then surged by 100.0% to -$1.8 million in 2024, then slumped by 42072.1% to -$748.1 million in 2025.
• The last three Retained Earnings figures came in at -$748.1 million (Q4 2025), -$735.1 million (Q3 2025), and -$724.2 million (Q2 2025), per Business Quant data.